LDS won the “Novartis Oncology” prize at the sixth edition of BioInItaly Investment Forum 2015 & Intesa Sanpaolo StartUp Initiative, the yearly investment forum open to established biotech and healthcare companies, start-ups and projects from Italy but also from other European countries seeking for financial resources and strategic partnerships. The event – in partnership with Assobiotec, Fondazione Filarete and Assobiomedica – was held in Milan on April 21-22, at Palazzo Besana, Piazza Belgioioso.
In a unique end-to-end program, the applicants benefit from coaching, networking and direct contact with international investors through a series of focused events. The initiative is aimed to provide the applicants with the competences, connections and access to potential Investors they need to go to market and scale.
During the event The Novartis Award was assigned to Lead Discovery Siena as the most promising oncology research project and start-up, as evaluated by Novartis Oncology Italy among all applicants. In particular, the project presented by LDS focused on the development of new drug for the treatment of Glioblastma Multiforme, a rare brain tumor. The award entailed a trip to Basel Campus, one of Novartis’ leading worldwide oncology research center, with coverage of travel and accommodation expenses.
http://assobiotec.federchimica.it/media-e-news/biotech-newsletter/n.-8-anno-xvi